Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites

The psychedelic alkaloid ibogaine is increasingly used as an oral treatment for substance use disorders, despite being unlicensed in most countries and having reported adverse events. Using wild-type and genetically modified mice, we investigated the impact of mouse (m)Abcb1a/1b and Abcg2 drug efflu...

Descripción completa

Detalles Bibliográficos
Autores principales: F. Martins, Margarida L., Heydari, Paniz, Li, Wenlong, Martínez-Chávez, Alejandra, Venekamp, Nikkie, Lebre, Maria C., Lucas, Luc, Beijnen, Jos H., Schinkel, Alfred H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931498/
https://www.ncbi.nlm.nih.gov/pubmed/35308219
http://dx.doi.org/10.3389/fphar.2022.855000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931498/
https://www.ncbi.nlm.nih.gov/pubmed/35308219
http://dx.doi.org/10.3389/fphar.2022.855000

Ejemplares similares